Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meet
PALO ALTO, Calif. , June 08 /Businesswire/ - @ImmuneOnc presents IO-202 Phase 1 data in patients with relapsed or refractory AML and CMML at the EHA annual meeting 2023 and announces @US_FDA #FastTrackDesignation to IO-202 for the treatment of relapsed or refractory CMML.